Human female reproductive system

Aspira Women’s Health Inc. to Report Second Quarter 2021 Financial Results on August 12

Retrieved on: 
Tuesday, July 27, 2021

About Aspira Womens Health Inc.

Key Points: 
  • About Aspira Womens Health Inc.
    Aspira Womens Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.
  • Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.
  • OVA1 plus includes our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses.
  • With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research.

ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting

Retrieved on: 
Friday, July 2, 2021

PGF2 is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture.

Key Points: 
  • PGF2 is believed to induce contractions of the myometrium and also upregulate enzymes causing cervix dilation and membrane rupture.
  • In nonclinical studies, ObsEva has observed that ebopiprant markedly reduces spontaneous and induced uterine contractions in pregnant rats without causing the fetal side effects seen with non-specific prostaglandin inhibitors such as indomethacin.
  • ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health and pregnancy.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment

Retrieved on: 
Monday, June 14, 2021

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is honored to announce it has filed an international patent application for a novel cannabis-based Vaginal Moisturizer and Lubricant Treatment.

Key Points: 
  • Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - June 14, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is honored to announce it has filed an international patent application for a novel cannabis-based Vaginal Moisturizer and Lubricant Treatment.
  • The composition comprises cannabinoids and additional agents of a phytoestrogen and hyaluronic acid and may be applied to alleviate vaginal dryness and vaginal atrophy.
  • Vaginal moisturizers and lubricants are applied to help overcome vaginal dryness and solve intercourse difficulties.
  • Vaginal dryness is a common condition faced by women of all ages; however, it is particularly common during and after the menopause transition.

SCYNEXIS Confirms that BREXAFEMME® (ibrexafungerp tablets) Qualifies for 10 Years of Regulatory Exclusivity for Vaginal Yeast Infections

Retrieved on: 
Wednesday, June 9, 2021

This exclusivity will be added to any other applicable exclusivity periods, such as the five years of new chemical entity (NCE) exclusivity, for a combined ten-year period of regulatory exclusivity.

Key Points: 
  • This exclusivity will be added to any other applicable exclusivity periods, such as the five years of new chemical entity (NCE) exclusivity, for a combined ten-year period of regulatory exclusivity.
  • We will also continue to work hard to fully leverage this regulatory exclusivity and our long patent protection to advance our pipeline of ibrexafungerp indications.
  • VVC, commonly known as a vaginal yeast infection due to Candida, is the second most common cause of vaginitis.
  • Typical VVC symptoms include pruritus, vaginal soreness, irritation, excoriation of vaginal mucosa and abnormal vaginal discharge.

PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting

Retrieved on: 
Tuesday, June 8, 2021

An additional four (4) HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.

Key Points: 
  • An additional four (4) HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.
  • Most types of HPV-related cancers (anal, cervical, head and neck, vaginal and vulvar cancers) were represented among the study subjects.
  • The company is hosting a conference call tomorrow morning at 8:00 am ET to discuss the data presented at ASCO.
  • The companys lead investigational cancer immunotherapy product PDS0101 is currently in Phase 2 clinical studies in HPV-associated cancers.

Fertility Focus Announces Launch of OvuFirst Skin-Worn Sensor to Add Support for Women Starting Out on Their Journey to Pregnancy

Retrieved on: 
Monday, June 7, 2021

The OvuSense App then uses this information to provide women with a full 8-day fertile window at the start of their next cycle.

Key Points: 
  • The OvuSense App then uses this information to provide women with a full 8-day fertile window at the start of their next cycle.
  • In a side-by-side study volunteers wore the OvuCore vaginal sensor and OvuFirst skin sensor overnight for several cycles.
  • OvuFirst provided me with a non-invasive way to collect data and see trends to better understand my personal health.
  • To learn more about the OvuSense fertility monitoring family, visit ovusense.com .

Aspira Women’s Health to Reveal 3rd Generation Ovarian Cancer Risk Assessment Technology at ASCO 2021

Retrieved on: 
Thursday, May 13, 2021

The product is expected to be available in Q4 2021.\n\xe2\x80\x9cWe are excited to have our abstract accepted and presented at ASCO.

Key Points: 
  • The product is expected to be available in Q4 2021.\n\xe2\x80\x9cWe are excited to have our abstract accepted and presented at ASCO.
  • This provides the first reveal of the performance of our new OVASight technology,\xe2\x80\x9d stated Valerie Palmieri, President, and CEO of Aspira Women\xe2\x80\x99s Health.
  • Aspira Women\xe2\x80\x99s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.
  • With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women\xe2\x80\x99s Health is delivering a portfolio of pelvic mass products over a patient\xe2\x80\x99s lifetime with our cutting-edge research.

Global Vaginal Laxity Market (2021 to 2025) - Featuring Viveve Medical, Almirall, Hologic and Fotona Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021

b'A wide number of treatments are available for vaginal laxity, which help women to regain their shape post child birth.

Key Points: 
  • b'A wide number of treatments are available for vaginal laxity, which help women to regain their shape post child birth.
  • Some of the popular treatments for vaginal laxity are: kegel exercise, vaginal cones, tightening creams, vagina rejuvenation and reconstructive surgery.\nThe global vaginal laxity market has shown rising trends over the past few years and is anticipated to grow at a significant growth rate over the forecasted period i.e.
  • Drivers that are and would support the growth of the market are multiple normal delivery under proper attendant, application of forceps during childbirth, etc.\nThe market is expected to grow on the back of developing technology, emergence of genital aesthetics, etc.
  • However, the market is facing some challenges such as aftereffects associated with vaginal tightening surgery, high surgery cost, etc.\n'

Aspira Women’s Health Inc. to Report First Quarter 2021 Financial Results on May 13

Retrieved on: 
Wednesday, May 5, 2021

b'About Aspira Women\xe2\x80\x99s Health Inc.\nAspira Women\xe2\x80\x99s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women\xe2\x80\x99s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.

Key Points: 
  • b'About Aspira Women\xe2\x80\x99s Health Inc.\nAspira Women\xe2\x80\x99s Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming women\xe2\x80\x99s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women.
  • Aspira Women\xe2\x80\x99s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.
  • OVA1\xc2\xae plus includes our FDA-cleared products, OVA1\xc2\xae and OVERA\xc2\xae, to detect risk of ovarian malignancy in women with adnexal masses.
  • With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women\xe2\x80\x99s Health is delivering a portfolio of pelvic mass products over a patient\xe2\x80\x99s lifetime with our cutting-edge research.

SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections

Retrieved on: 
Friday, April 30, 2021

b'The VANISH-306 study evaluated the safety and efficacy of oral ibrexafungerp as a treatment for patients with VVC (mITT 272 subjects).

Key Points: 
  • b'The VANISH-306 study evaluated the safety and efficacy of oral ibrexafungerp as a treatment for patients with VVC (mITT 272 subjects).
  • Severe VVC patients (VSS>7), categorized as complicated patients, accounted for 91.9%% of the patients in the in the study.
  • Typical VVC symptoms include pruritus, vaginal soreness, irritation, excoriation of vaginal mucosa and abnormal vaginal discharge.
  • The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.